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Abstract
Global regulatory guidance for post approval changes to chemisty manufacturing controls
(CMC) of commercial drug products lack harmonisation. Implementation of post-approval
changes are slow and complex which can lead to supply issues of medicinal products with
little or no continuous improvements to manufacturing processes being made. ICH Q12
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
was published in November 2019. This guideline provides a framework to facilitate the
management of post-approval CMC changes in a more predictable and efficient manner.
Tools and enablers in the guidline aim to enhance the transparency between the industry
and the regulatory authorities while promoting innovation and continual improvementt.
This research paper explores the advantages of implementing ICH Q12 through a literature
review, 2 industry based case studies that demonstrate the use of the regulatory tools
which are described in the guideline and subject matter experts (SMEs) were interviewed
for their opinions on post approval change management.

Introduction

The goal of any pharmaceutical manufacturing company is to make safe effective medicines
of high quality in a cost effective manner to enable realisation of products to patients.
Improvements to the manufacturing process and test methods should also be an important
priorty for pharmaceutical companies. As new knowledge is discovered throughout the
lifecycle of a product, continuous improvements must be made in order for a company to
achieve its full potential, eliminate any supply disruptions, reduce patient risk and improve
compliance. Quality of a drug product and its process effectiveness can, and should be
demonstrated throughtout its entire lifespan. Without implementing changes along the way
there would be no improvements.
At the time of writing this paper there is a global COVID-19 pandemic which is causing
unprecedented challenges for the supply of medicines around the world. New guidance and
changes have been made by regulatory agencies globally in order to minimise the risks of
drug shortages, while at the same time ensuring the high standards of quality, safety, and
efficacy of the medicines available to patients. The EU regulatory authority the European
1
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Medicines Agency (EMA) has pubished a questions and answers document on regulatory
expectations for medicinal products for human use [1]. The aim of the EU legislation is to
ensure a high level of public health is maintained, while providing regulatory flexibility. The
US regulatory authority the Food and Drug Administration (FDA) have established an
‘emergency use authorisation authority’ [2] which allows FDA to strengthen the nation’s
public health protections by facilitating the availability and use of medical countermeasures
needed during public health emergencies. This pandemic has proven that global regulatory
flexibility is achievable when the level of risk to public health is at high. From the availablilty
of medicines to clinical trials, industry and regulatory changes have been focused on
minimising risks of drug shortages while maintaining the priority of quality, safety, and
efficacy of medicines.
The International Council for Harmonisation (ICH) provide quality guidelines across the
product lifecycle including: Q8(R2) Pharmaceutical Development [3], (Q9) Quality Risk
Management [4], (Q10) Pharmaceutical Quality System [5] and (Q11) Development and
Manufacture of Drug Substances [6] which document opportunities for science and riskbased approaches for assessing and managing changes. However, it is clear from recent
drug shortages that there are still challenges for both industry and regulatory bodies which
limit in paticular any benefits from improvements being made in the commercial stage of
the pharmaceutical lifecycle. In paticular the process for post approval changes (PAC) for
innovation and continuous improvement has been identified as an area that needs more
focus[7].
Building on the ICH Q8-Q11 series of guidelines, ICH Q12 Technical and Regulatory
Considerations for Pharmaceutical Product Lifecycle Management [8] was finalised in
Novmber 2019. This guideline addresses the commercial (post approval) phase of the
product lifecycle and it both complements and adds to the flexible regulatory approaches to
post-approval Chemistry Manufacturing Control (CMC) changes described in ICH Q10 Annex
1. ICH Q12 provides a framework to facilitate the management of post-approval CMC
changes in a more predictable and efficient manner. A harmonised approach regarding
technical and regulatory considerations for lifecycle management should benefit patients,
industry, and regulatory authorities by promoting innovation and continual improvements
in the pharmaceutical sector, strengthening quality assurance and improving supply of
medicinal products. It also demonstrates how increased product and process knowledge
2
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can contribute to a more precise and accurate understanding of which PACs require a
regulatory submission, as well as including definitions of the level of reporting categories for
such changes. A science and risk based approach for identifying regulatory requirements is
used. ICH Q12 should complement the other harmonization guidelines (ICH Q8 to Q11).
This paper presents the findings of a research study carried out for a Masters Dissertation at
TU Dublin which explores the implemention of ICH Q12 using the following methodology:
1. Review of Literature.
2. Two Industry Case Studies.
3. Subject Matter Expert (SME) Interviews.

1. 0

Review of Literature

Firstly, a review of the relevant regulations including the ICH quality guidelines Q8-Q11 was
carried out in order to gain an understanding of the guidance each gives

over a

pharmaceutical products lifecycle, in particular guidance pertaining to change management.
A review of the new ICH Q12 guideline was also carried out.
After reviewing ICH quality guidelines, a detailed look at the The Pharmaceutical Inspection
Co-Operation Scheme (PIC/S) [10] paper was carried out. This PIC/S paper provides practical
guidance for GMP inspectors when seeking to evaluate the effectiveness of a company’s
pharmaceutical quality system (PQS) in relation to risk-based change management.
This was followed by a review of the Post Approval Change Literature provided by The
World Health Organisation (WHO) [11], the US Food and Drug Administration (FDA) [12], the
European Medicines Agency (EMA) [13] and the Japanese Pharmaceutical and Medical
Devices Agency (PDMA) [14].
Finally, two recent publications in relation to post approval change in the pharmaceutical
industry were also reviewed namely: Industry One-Voice-of Quality Concept Paper: Solving
the Global Continual Improvement and Innovation Challenge: How an Effective
Pharmaceutical Quality System Can Transforms Post-Approval Change Management [15]
and the Industry One-Voice-of-Quality (1VQ) Solutions, Effective Management of PostApproval Changes in the Pharmaceutical Quality System (PQS) - Through Enhanced Science
and Risk-Based Approaches” [16] paper.

3
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The purpose of the literature review was to understand how post approval change is
managed within the pharmaceutical industry and what guidance the pharmaceutical
industry has for executing post approval changes. Also, the review of literature aimed to
understand why ICH Q12 was published.
1.1

ICH Quality Guidelines

ICH Q8 (R2): Pharmaceutical Development
This guideline describes the suggested contents for Section 3.2.P.2 (Pharmaceutical
Developement) of a regulatory submission by a Pharmaceutical Company for Market
Authorisation of a product, using the ICH Common Technical Document (CTD) format. [3]
The Pharmaceutical Development section of the ICH Q8 (R2) guideline provides the Market
Authorisation Holder (MAH) an opportunity to present the knowledge gained through the
application of scientific approaches and quality risk management (ICH Q9 QRM) to the
development of a product and its manufacturing process. It is first produced for the original
marketing application and can be updated to support new knowledge gained over the
lifecycle of a product. It is intended to provide a comprehensive understanding of the
product and manufacturing process for reviewers and inspectors. The guideline also
indicates areas where the demonstration of greater understanding of pharmaceutical and
manufacturing sciences can create a basis for flexible regulatory approaches. ICH Q8 also
describes the Quality by Design (QbD) approach where changes within the design space can
be made without submission of a prior notification to regulators.
The Pharmaceutical Development section of the ICH Q8 (R2) guideline provides the Market
Authorisation Holder (MAH) an opportunity to present the knowledge gained through the
application of scientific approaches and quality risk management (ICH Q9 QRM) to the
development of a product and its manufacturing process. It is first produced for the original
marketing application and can be updated to support new knowledge gained over the
lifecycle of a product. It is intended to provide a comprehensive understanding of the
product and manufacturing process for reviewers and inspectors. The guideline also
indicates areas where the demonstration of greater understanding of pharmaceutical and
manufacturing sciences can create a basis for flexible regulatory approaches. ICH Q8 also
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describes the Quality by Design (QbD) approach where changes within the design space can
be made without submission of a prior notification to regulators.
ICH Q9: Quality Risk Management (QRM)
This guideline gives principles and examples of tools that can enable effective and
consistent risk based decisions, both by regulators and industry, regarding the quality of
drug products across the product lifecycle. [4] ICH Q9 gives guidance to companies on how
to carry out risk assessments for changes, and suggests that the level of rigor in carrying out
the risk assesment should be commensurate with the level of risk to the quality, safety and
efficay of the drug.
ICH Q10: Pharmaceutical Quality System
This guideline describes the elements and enablers for an effective pharmaceutical quality
system based on International Standards Organization (ISO) quality concepts, and applicable
Good Manufacturing Practice (GMP) regulations.. Figure 1 shows the ICH Q10
Pharmacecutical Quality System elements and enablers. Change management system is one
of the elements which contributes to an effective pharmaceutical quality system (PQS).
According to ICH Q10:
‘The change management system ensures continual improvement is undertaken in a timely
and effective manner. It should provide a high degree of assurance there are no unintended
consequences of the change [5].
Contineous improvement is based on increased product and process knowledge, enhanced
science and risk-based assessment of changes. A pharmaceutical company should be able to
predict the effect that the change will have on product quality. Change Management within
an effective and robust PQS should contribute to a greater level of manufacturing control,
which subsequently strengthens the confidence Regulatory Authoritiess have in a
company’s ability to consistently produce high quality products. A risk-based assessment of
changes managed through an effective PQS can ultimately lead to greater regulatory
flexibility. Effective change management should result in improving product quality, process
performance, state of control, and product availability.
5
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Figure 1: ICH Q10 Pharmaceutical Quality System Elements and Enablers, ICH Q10 (5).

ICH Q11 Development and Manufacture of Drug Substances
Similar to ICH Q8, the ICH Q11 guideline describes approaches to developing and
understanding the manufacturing process of the drug substance, and also provides guidance
on what information should be provided in Module 3 of the Common Technical Document
(CTD) Sections. In addition, ICH Q11 provides further clarification on the principles and
concepts described in ICH Guidelines on Pharmaceutical Development (Q8), Quality Risk
Management (Q9) and Pharmaceutical Quality System (Q10).
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle
Management
The ICH Q12 guideline provides a framework to facilitate the management of post-approval
CMC changes in a more predictable and efficient manner. [8] This guideline addresses the
commercial phase of the product lifecycle and it both complements and adds to the flexible
regulatory approaches to post-approval CMC changes described in ICH Q8(R2) and ICH Q10
Annex 1. ICH Q12 demonstrates how increased product and process knowledge can
contribute to a more precise and accurate understanding of which post-approval changes
require a regulatory submission. Increased knowledge and effective implementation of the
tools and enablers described in the guideline enhances a company’s ability to manage CMC
changes effectively within the company’s Pharmaceutical Quality System (PQS) with less
6
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need for extensive regulatory oversight prior to implementation. The extent of operational
and regulatory flexibility and its adequate implementation is subject to the regulatory
framework in place, as well as product and process understanding (ICH Q8(R2) and ICH
Q11), application of quality risk management principles (ICH Q9), and an effective
pharmaceutical quality system (ICH Q10).
One of the concepts discussed in the ICH Q12 guideline are “Established Conditions” (ECs)
which are defined as:
‘Legally binding information considered necessary to assure product quality which have been
agreed between the MAH and regulatory authorities. ‘[8]
This guideline describes scientific and risk-based approaches a pharmaceutical company can
use to define ECs and their reporting categories. The extent of identifying ECs will vary from
company to company based on development approaches and product and process
understanding. The guideline outlines the approaches to define ECs for manufacturing
processes and analytical procedures.
For manufacturing processes, the following are considered when identifying ECs:
•

Unit operation and sequence of steps

•

The overall control strategy, inputs and outputs that are necessary to assure
product quality (process parameters, material attributes and in-process controls)

•

The key process parameters (KPPs) that may not be directly linked to critical
product quality attributes but need to be tightly controlled to assure process
consistency as it relates to product quality.

A decision tree shown in Figure 2 below is provided in the guideline, which illustrates a
stepwise approach for identification of established conditions and associated reporting
categories for manufacturing process parameters.

7
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Figure 2: Decission tree for Identification of EC and Reporting Categories, ICH Q12 [8].

There are different approaches defined in ICH Q12 which can be used alone or in
combination to identify ECs for manufacturing processes. There are as follows:
•

A parameter-based approach: in which product development prior to
regulatory submission provides a limited understanding of the relationship
between inputs and resulting quality attributes. This approach will include
many inputs (e.g., process parameters and material attributes) along with
outputs (including in-process controls).

•

An enhanced approach: in which with increased understanding of interaction
between inputs and product quality attributes together with a corresponding
control strategy ECs can be identified, such that they are focused on the most
important input parameters along with outputs.

•

In certain cases, applying knowledge from a data-rich environment enables a
performance-based approach in which ECs could be primarily focused on
control of unit operation outputs rather than process inputs (e.g., process
parameters and material attributes).

In ICH Q12 approaches for identifying ECs for analytical procecdures are also discussed and
they are similar to the principles of the manufacturing process described above. They
include elements which assure performance of the procedure. The different approaches in
identifying ECs for them are:

8
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When more limited development studies have been conducted this may
result in a narrow operating window to ensure method performance. In such
cases ECs may be more extensive with fixed and/or tight conditions.

•

Enhanced understanding can lead to a wider operating window that ensures
method performance, where ECs can be reduced and focused on method
performance (e.g., method parameters acceptable ranges rather than set
points, performance criteria).

For successful implementation of ICH Q12 a pharmaceutical company must first identify ECs
and then categorise them into reporting levels. The categorisation of post-approval CMC
changes is described in a framework that encompasses a risk-based categorisation for the
type of communication expected of the Marketing Authorisation Holder (MAH) with the
regulatory authority.
The categories are dependent on the potential risk to quality, safety and efficacy. The type
of communication can be either a prior approval (you can’t implement change until
approved) or a notification (a change can be made and approval from regulation comes
after). For example, a high risk change like changing a critical parameter specification would
require prior notification. Low risk changes can be notifications after the implementation of
change. All other changes, which are non-ECs, can be managed within the company’s PQS.
Risks relating to changes are still assessed and documented within the PQS. Assessments
are made to determine impact on regulatory compliance, quality, and product control
strategy, as well as the necessity to revalidate the process.
Another concept ICH Q12, introduces is that of the “Post Approval Change Management
protocol” (PACMP) which , can potentially save a lot of time for companies by having an
upfront agreement between the MAH and regulatory authority of how CMC changes can be
implementated. Figure 3 below describes how ICH Q12 proposes a possible 2 step method
to make changes.
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1: Decision, proposal and approval: Submission of a written protocol that describes
the proposed change(s), its rationale(s), risk
management activities, proposed studies and
acceptance criteria to assess the impact of the
change(s), other conditions to be met (e.g.,
confirmation that there is no change to the
approved specification), the proposed reporting
category for the change(s), and any other
supportive information. This protocol is
reviewed and approved by the regulatory
authority in advance of execution of the
protocol.

Technological University Dublin

2: Implementation: - The tests and studies
outlined in the protocol are performed. If the
results/data generated meet the acceptance
criteria in the protocol and any other conditions
are met, the MAH submits this information to
the regulatory authority according to the
categorisation (classification) in the approved
protocol for review by the regulatory authority
as appropriate. Depending on the reporting
category, approval by the regulatory authority
may or may not be required prior to
implementation of the change

Figure 3: The 2 Step Application of PACMP, ICH Q12. [8]

ICH Q12 has more information on other tools and enablers such as the product lifecycle
managment (PLCM) which serves as a central repository for the ECs and the associated
reporting category for changes made to ECs. ICH Q12 states that an effective PQS as
described in ICH Q10 and compliance with regional GMPs are necessary to gain full benefit
from the ICH Q12 guideline. Good commnication between assessors and inspectors
facilitates the use of the tools included.
1.2

Guidance for GMP Inspectors

Typically GMP inspectors turn to the The Pharmaceutical Inspection Co-Operation Scheme
(PIC/S) for guidance, and in November 2019 practical guidance for GMP inspectors for
evaluateing the effectiveness of a company’s PQS in relation to risk-based change
management was published [10]. From the regulator’s perspective, (PIC/S) guidance
describes how a companies PQS should drive risk reduction, where possible, to ensure
better quality performance, manufacturing performance, continual improvement and
innovation, through adequate and timely management of product quality and patient safety
risks. The guidance evaluates the effectiveness under the sections shown in Figure 4:
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Change Proposals

Risk Assessments

• The reason for
change. Changes
in relation to
upgrades,
manufacturing
performance
improvements,
CAPAs,
innovation and
CI

• The level or
rigor, effort and
documentation
commensurate
with the level of
risk. The
evalution of the
change should be
robust by the
app appropriate
SMEs to identify
all required
actions
necessary to
implement the
change. Risks are
adequately
assessed for
potential risks
and benefits to
product quality,
safety and
efficacy.

Technological University Dublin

Change
Implementation
• Execution of the
actions within
the pre approved
change plan
completed and
documented. The
outcome of risk
assessment and
levels allow for
planning,
prioritising and
implementation.

Change Review
and Effectiveness
• QA Verify all
actions/
deliverables
have been
satisfied. Have
the changes met
their intended
objectives and
pre-defined
effectiveness
criteria. Residual
risks assessed
and managed to
acceptable levels
and the changes
being monitored
to ensure
control.

Figure 4: Summary of PIC/S Guidance for Evaluating PQS Effectiveness for Change Management. (Source: Susan McDonagh November
2020)

1.3

Additional Regulatory Guidance for Post Approval Change

A review of the additional regulatory guidance provided by the World Health Organisation
(WHO), the Food and Drug Administration (FDA), European Medicines Agency (EMA) and
The Pharmaceuticals and Medical Devices Agency (PDMA) was carried out to understand
how post approval change is managed these regions. As there are a many pharmaceutical
global markets these four were chosed for reivew as these agencies represent some of the
largest markets in the world.
World Health Organisation
The World Health Organisation (WHO) works worldwide to promote health and keep the
world safe. Support is provided to its member states for changes of approved
biotherapeutic products in order to resolve complexity and current challenges of global lifecycle management. The categories of changes and reporting procedures are provided, as
well as the data requirements to support the proposed changes. [11]
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Food and Drug Administration
The Food and Drug Administration (FDA) which is the United States of America’s governing
body for pharmaceutical products, provides a guidance protocol for drug manufactureres to
assist them in determining which reporting category is appropriate for a post approval
change in chemistry, manufacturing, and controls (CMC) [12]. This guidance describes the
general and administrative information on reporting and evaluating changes and
recommendations for reporting categories are based on a tiered-reporting system for
specific changes.
European Medicines Agency
The Eurpean Medicines Agency (EMA) is a decentralized agency of the European Union (EU)
responsible for the scientific evaluation, supervision and safety monitoring of medicines in
the EU. They provides a post approval change protocol for guiding the implementation of a
change during the lifecycle of the product and how these would be prepared and verified. It
is a stepwise approach in the assessment of changes, which allows an early evaluation of the
strategy for the change and a later separate evaluation of the data produced based on the
agreed strategy. Such a stepwise approach is expected to lead to faster and more
predictable implementation of changes post-approval, since the MAH will have obtained
agreement from the Regulatory Authorities on the proposed strategy and tests to verify the
effect of the change on product quality.
Pharmaceutical and Medical Devices Agency
The Pharmaceuticals and Medical Devices Agency (PDMA) which is the government
organisation in Japan responsible for ensuring safe effective medicines on the Japanese
market have two reporting categories for post approval change; minor change notification
and partial change approval. Partial change applications (PCA) are described in Article 14,
Paragraph 9 and 10 of the Pharmaceutical and Medical Device Act (PMDA). [14]
1.4

Recent Publications

The final part of the literature review focused on two industry papers to understand the
perspective amongst the pharmaceutical industry of the current status of post approval
change management in the pharmaceutical industry, “Industry One-Voice-of-Quality (1VQ)
12
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Solutions: Effective Management of Post-Approval Changes in the Pharmaceutical Quality
System (PQS)—through Enhanced Science and Risk-Based Approaches” [16] and the prior
concept paper: “Industry One-Voice-of Quality Concept Paper: Solving the Global Continual
Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System
Can Transforms Post-Approval Change Management”. [15] These papers are sponsored and
endorsed by senior quality leaders (Chief Quality Officers and Heads of Quality) from more
than 20 global pharmaceutical companies who have collaborated to speak with “One-VoiceOf-Quality” (1VQ).
The concept paper written in 2019 explains the global regulatory complexity for approval of
post approval changes. It states that there is:
“ a global problem that needs a global solution” [15]
Post approval changes are taking years for worldwide approval slowing down
implementation of changes and continous improvements which can lead to drug shortages.
An essential element to solving this problem is global quality leaders speaking with one
unified voice. The authors propose solutions in this paper that will help overcome the drug
shortage problem in the world. They state that an alligned standardised industry approach is
needed along with having practical tangible tools for change management. The paper calls
out the need for the following:
1. Define and demonstrate effective management of post-approval changes (PACs) in
the pharmaceutical quality system (PQS) (during review and inspections) so that
more changes can be managed in the PQS and be reported via notification pathways
(e.g. annual report or changes-being-effected) instead of prior approvals, without
negatively impacting risk to patient and drug product efficacy and quality.
2. Develop standard risk-based assessment of PACs that incorporates latest product
and process knowledge.
3. Pilot the proposed solutions for PACs with a limited number of companies. Seek
input from regulatory agencies on outcomes.

13
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The authors wish to encourage a dialog among regulators to provide guidance on measures
of an effective PQS and how to demonstrate its effectiveness during PAC reviews and
inspections.
The follow up solutions paper which was published in 2020 again discusses the challenges
that global regulatory compelxity brings and the “wicked problem”[16] of drug shortages as
a result of this. The document expands on the deliverables from the concept paper
presenting solutions. There is a thorough explanation with added specific details for the 4
PQS elements and 2 enablers (as described in ICH Q10) on how a company can leverage the
PQS to effectively manage post approval changes through enhanced science and risk-based
approaches.
1.5

Learnings from the Literature Review

The key take aways from the review of the ICH quality guidelines Q8(R2), Q9, Q10 and Q11
is that each of these guidelines are inter-related and should be used in parallel with each
other to ensure efficient change management. The ICH guidelines in particular ICH Q8(R2)
and ICH Q10 promote opportunities for pharmaceutical companies to manage changes
within their PQS and gain regulatory flexibilty as a result of the increased product and
process knowledge and science and risk-based approaches to change, yet there was a need
for additional guidance in relation to post approval change, therefore ICH Q12 was
published.
To implement ICH Q12 successfully a pharmaceutical company needs to use the harmonised
regulatory tools and enablers with associated guiding principles, as described in the
guideline. This will enhance the management of post-approval changes, and transparency
between industry and regulatory authorities, supporting innovation and continual
improvement. A key enabler of ICH Q12 is an effective PQS as described in ICH Q10.
The PIC/S guidance for inspectors requires companies to demonstrate the effectiveness of
their PQS. From this paper inspectors are provided with examples of how risk-based
approaches to change management can be demonstrated practically by pharmaceutical
companies. This paper is alligned with demonstrating an effective PQS outlined ICH Q10

14
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Annex 1 and the premise is that if an effective PQS can be demonstrated there is potential
for risk-based regulatory oversight for companies.
In relation to the global guidances for post approval change in the pharmaceutical industy,
each market has specific guidance depending on the market a pharmaceutical comapny
supplies their drug product to and each of them differ. Table 1 below shows different types
of reporting categories for changes to the different regulatory agencies, further showing
that there is a lack of harmonisation among them.

Impact

WHO

EU

US

Type II Variation
High

Major

(application for

Prior Approval

Variation

approval of

Supplemement

variation)

Japan
Partial Change
Application
(prior)

Type IB Variation

Moderade

(notification

Supplement of

before

Changes being

Minor Change

implementation

Effected in 30

Notification

Moderate

and MAHs must

days

(within 30 days

Variation

wait a period of 30

after

days)

Supplement of

implementation/

Type IAIN variation

Changes Being

shipping)

(immediate

Effected

notification)
Type IA Variation
Low

Minor

(notification within

Variation

12 months after

Annual Report

Non Approved
Matters

implementation)

Table 1: The Current Reporting Categories for Regulatory Agencies for PAC. (Source: Susan McDonagh Novemeber 2020)
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Finally, the review of recent publications, gave insights into how chief quality officers and
quality leaders from 20+ pharmaceutical companies have collaborated and are now
speaking with a unified voice with a goal to implement changes faster and tackle the
problem of drug shortages in the world.
Implementation of the solutions presented in the “Industry One-Voice-of Quality Concept
Paper: Solving the Global Continual Improvement and Innovation Challenge: How an
Effective Pharmaceutical Quality System Can Transforms Post-Approval Change
Management” paper could help achieve a transformational shift with faster implementation
of new knowledge, continual improvement, and innovation through post-approval changes.
2.0

Case Studies

On completion of the literature review a practical analysis of some of the regulatory tools
and enablers in ICH Q12 was carried out with a view to understanding their proposed
advantages. Three of the 8 tools in the guideline were assessed through 2 industry case
studies as follows:
-

Established Conditions (ECs) and the categorisation of post approval Chemistry

Manufacturing Controls (CMC) changes - Evaluated in Case Study 1
-

The Post Approval Change Management Protocol (PACMP) – Evaluated in Case

Study 2
The case studies were conducted in a global biopharmaceutical company. The company
manufactures vaccines by means of aseptic processing involving the following steps: buffer
preparation, formulation and aseptic syringe filling. Processing is carried out in cleanrooms
using pharmaceutical production equipment; product vessels and a Grade A isolator. The
commercial vaccine drug product has been on the market for many years thus there is a
data rich environment available.
2.1

Case Study 1

Established Conditions
Case Study 1 focused on the Established Conditions (ECs) for the buffer preparation,
formulation and aseptic syringe filling process and process controls which were by
16
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presented by the company at the time of regulatory approval, in Module 3 (3.2.P.3.3)
‘manufacturing: description of manufacturing process and process controls’ of the CTD.
As part of this case study, 96 EC process parameters from the buffer preparation,
formulation and aseptic syringe filling processes were evaluated with a view to identifying
the post approval change reporting categories for each. The performance-based approach
and the decision tree in ICH Q12 as discussed section 1.1 and shown in Figure 2, was used to
assign these reporting categories. This approach was chosen as the process has been in
place for many years and there is sufficient product and process understanding.
Prior to this study the company had assessed the changes using QRM, and had identified the
criticality of the process parameters. 33 of these were identified as critical process
parameters (CPP) or material attributes that are known to have an impact on a critical
quality attribute (CQA) and therefore need to be controlled in order to ensure quality. 63 of
the process parameters were identifited by the company as non-critical. Figure 5 below
summarises the controls that were identified as critical.
Formulation (16)

Buffer Preparation
(9)
Weighing NaOH, WFI QS,
Weighing Succinate Buffered
Saline, Weighing surfactant,
Succinate Buffered Saline
QS, Weighing NaCL,
Weighing Succinic Acid, pH
adjustment, pH
measurement

Pre use integrity test
pressure, initial succinate
buffered saline addition,
addition of surfactant, QS of
conjugate pooling vessel,
charge from buffer vessel to
conjugate pool, calculation
of succinate saline volume to
add, final QS of succinate
saline, sterile filtration time,
post use integrity test, pre
use adjuvant can integrity
test, Adjuvant can mixing
rate, Adjuvant can mixing
time prior to download, time
prior to sampling, weight of
Adjuvant can added, mixing
parameters in formulation
vessel, formulated batch
weight

Aseptic Syringe
Filling (8)
Vessel pressure decay test,
mixing speed in vessel,
filling speed, filling weigh,
head space, stopper
position, turbidity, filling
time.

Figure 5: Critical Process Parameters Identfied in Case study 1 (Image source Susan McDonagh November 2020)

The study evaluated these controls for post approval changes reporting categories and
found that any changes to the 63 non-critical parameters should only require a notification
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to regulatory authorities, as per the decission tree in ICH Q12. Changes to these can be
implemented without delay and they are managed within the PQS. This approach allows
operational flexibility and the potential for continual improvement.
By identifying ECs for this process and categorising them correctly, it was shown that the
company would have the oportunity to manage 63 out of 96 potenitial changes within its
PQS. This large number of ECs identified as notifications would allow the company speed up
the implementation of these changes, thus enabling real time continuous improvement, by
avoiding any delays regulatory prior submissions may take.
In order for a company to progress with this approach, an upfront agreement with
regulators is required. This agreeement covers the following 2 key elements:
•

All EC for processes and materials are predetermined , agreed and approved.

•

The company must be able to demonstrate to regulators that they have an effective
PQS system in place which is capable of prediciting changes made to process
parameters impact to quality.

Categorisation of Post Approval Changes
The second part of case study 1 took a deep dive into the various different reporting
categories assigned by global regulatory authorities for one change carried out by the
company in 2017.
This change was initiated in 2017, and involved the site of labelling, packaging and batch
release for vaccines moving from the UK to Europe. The regulatory impact of this required
98 market impact assessments which returned the following different notification
categories:
-

Change not applied. This identified that 19 market registrations did not identify
speciffically the site location for labelling, packaging and batch release.

-

Contingency. This identified that 4 market registrations, did not require a filing prior
to implementation. However, the change may not be implemented in these markets
18
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until submission and/or approval in another market, or submission and/or approval
of a separate filing in the same market, is complete. This is a placeholder to prevent
implementation in these markets until the submission/approval upon which it is
contingent is complete.
-

File in next annual report. This identified that 2 market registrations required filing
in the next Annual Report submission.

-

Notification prior to distribution. This identified that 11 market registrations
required health authority submissions prior to implementation of the change.

-

Prior approval variation type II. This identified that 59 market registrations required
health authority submission. Implementation of change may not occur until formal
health authority approval is received.

-

Type 1A. This identified that 1 market registration required health authority
submission within 12 months of implementation of the change.

-

Type 1B. This identified that 2 market registrations whose regulations allow
implementation some designated timeframe following submission (e.g.,
tell/wait/do). The change was implemented in accordance with timelines defined by
local regulations.

At the time of writing this paper, 11 of these markets status are still not in an “approved”
state and the change file is still open. As mentioned this company supplies product
worldwide therefore has to deal with many market authorities. The impact of the markets
not being harmonised is having a delay to the company impementing this change. 3 years
later and it is still open. This example highlights the need for harmonisation amongst
regulators. This scenario is illustrate elegently by the 1VQ team as follows:

Figure 6: http//:www.PRST/1vq [17]
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Case Study 2

Post Approval Change Management Protocol (PACMP)
Case Study 2 focused on a historical analysis of CMC changes for a commercial vaccine for
2017 and 2018. During that period the company dealt with a large volume of changes for
the vaccine (272). These changes were evaluated in the usual ‘traditional manner’ and
those requiring regulatory notifications were submitted accordingly. The rest were managed
within the companies PQS, Figure 7 below illustrates the breakdown of these on an annual
bases for the 2 years under review.

Changes Impacting Regulation and Changes
Managed Within PQS
150
100
50
0
CMCs Changes with Regulatory Impact 2017
PQS Change controls 2017
CMCs Changes with Regulatory Impact 2018
PQS Change controls 2018
Figure 7: Changes Impacting Regulation and Changes Managed within PQS. (Image source: Susan McDonagh, November 2020).

The changes that were made were all in the scope of contiunous improvements such as:
•

upgrades to equipment or facilities,

•

improvements in raw materials,

•

improvements to the manufacturing performance,

•

supply and capacity,

•

corrections from quality issues.

This study carried out a comparisson of the ‘tradition manner’ of documenting changes, as
described above, versus how these would be treated in the PACMP presented in ICH Q12.
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The ‘tradition manner’ documented all the the changes under the following headings:
1. Decision
This first phase of making a change is the decision phase. This is a formal discussion
followed by the agreement amongst SME’s and the relevant stakeholders that a change is
needed.
2. Proposal
The second phase is to propose the change to the relevent SMEs. All activities that are
needed to initiate, determine scope, assess the impact, decide recommended actions,
timelines and endorsements are documented. The scope and deliverables are clearly
defined. The reason for the change is clearly described as well as they type of change. The
current state, proposed state and the driver for the change are documented. Potential
impact assessments are documented and what they apply to.
3. Approval Phase
The third phase is the assessment of potential benifits and risks to product quality, safety
and efficacy.
4. Implementation Closure Phase
The final phase is confirmation that the delierables for the change are in place.
It was found in the study that the traditional manner in which the company has been
managing changes is comparable to the PACMP that is described in ICH Q12, which was
discussed previously in section 1.1 and Figure 3 of this paper.
Specifically:
•

The first step of the PACMP outlines the companys: decision, proposal and
approval. Describing the proposed change its rationale, risk management activities,
proposed studies and acceptance criteria to assess the impact of the change and
outline conditions to be met
21
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This is then followed by a regulatory approval step, where the protocol is reviewed
and approved by the regulatory authority in advance of execution.

•

The next step is implementation. The tests and studies that were outlined in the
protocol are carried out, and it is confirmed that they meet the acceptance criteria,
which was previously defined in step 1.

It is clear that for this company their traditional manner for implementing changes is aligned
with the ICH Q12 PACMP. However it must be noted that this may not be the case for all
companies.
Futhermore, Case study 2 observed that the PACMP method is reflective of the practical
guidance for GMP inspectors provided in the paper ‘How to Evaluate / Demonstrate the
Effectiveness of a Pharmaceutical Quality System in relation to Risk-based Change
Management,’ [10] for evaluating the effectiveness of a company’s PQS in relation to riskbased change management, as discussed in section 1.2 of this paper. In addition, the study
also observed that the PACMP is also comparable to the change management risk-based
assessment of PACs described by the One-Voice-of-Quality solutions paper ‘Industry OneVoice-of-Quality (1VQ) Solutions, Effective Management of Post-Approval Changes in the
Pharmaceutical Quality System (PQS) - Through Enhanced Science and Risk-Based
Approaches’ [16].

2.3

Learnings from the Case Studies

Casestudy 1 clearly identifies and illustrates the complex nature of making a change accross
several regulatory regions. The benefit of an harmonised approach is obvious, and would
greatly enhance the speed at which continuous improvement could be made, which can
only have a positive effect on the patient.
Casestudy 2, observes that for the company in question, there is clear alignment between
there current method of implementing changes, and the ICH Q12 proposed methods. This
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allignment is welcome from a companys perspective, and will go some way towords
harmonising post approval changes accross regions.
However, for companies with less mature Pharmaceutical Quality System, the allignment
may not be as clear.

3.0

Interviews with SMEs

The final part of the research study was interviews with Subject Matter Experts (SMEs), to
gain insights and understandings on the advantages of ICH Q12 guideline. Three such
inteviews were carried out, 2 with industry experts and 1 with a regulator. The topics
explored were:
•

Opinions on Established Conditions

•

Opinions on PACMP tool

•

Ways a company could demonstrate the effectives of their PQS

The first question posed to the SMEs was: “What are your opinions on the purpose of
“Established Conditions”?
The opinions of the SMEs were:

•

The idea of EC has always been around, for attributes that carry high risk and have
direct impact on product quality and patient safety.

•

While it is good to have a structured approach and an alligned definition, this is only
for ICH countries and does not solve the problem in the global sense as non ICH
countries don’t use this term.

•

A company must use good application of QRM and criticality assessments of
parameters to clearly identiy ECs.

•

Established Conditions new terminolgy is the same as “licenced parameters”.

•

Knowing in advance is helpful for planning how to support changes based on
knowing the requirements in terms of submission notification required to regulatory.
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The second question posed to the SME was in relation to the PACMP tool: “ How do you
think this tool will speed up change implementation?”
The opinions of the SMEs were:
•

The PACMP will enhance transparancy with regulators by having the agreements
upfront and this will help with the implementation of changes.

•

It is a good opportunity to manage changes as notifications , where some changes
can be downgraded.

•

The benefits of regulatory flexibility with this tool would be harmonising reporting
requirements and requirements across markets, this is fundamentally the ICH goal.
How long before we see benefits is quite variable, it starts imediately once you have
that regulatory flexibility, once you have agreed ECs and a PACMP with markets , in
those situations you would see the benefits right away..

The third question posed to the SMEs was: “Do you think the PIC/S paper and ICH Q10 and
ICH Q12 are robust enough for change management, are there any gaps?”

•

Yes, they are sufficient for one component of the PQS

•

Further development of guidance from PIC/S on the other elements within the PQS
would be good for industry as there is a need for practicle tangible tools and
examples to help them in demonstrating PQS effectiveness. This need for those tools
is obvious with the lack of regulatory flexibility in industry not currently happening in
spite of it being outlined in ICH Q10.

•

The PIC/S paper goes a long way towards giving companies solutions of how to
demonstrate the effectiveness of the PQS with regards to change management.

The final question explored how the effectiveness of post approval effectiveness could be
assessed or documented post closure. The question posed to the SMEs was: “How can a
company demonstrate PAC effectiveness?”
T
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he opinons of the SMEs were:
•

Having a good quality system in place is key.

•

The recent PIC/S paper checklist for companies, which is practical and easy to use, is
a good way for companies to ensure change management is robust.

•

Wouldn’t it be great if companies could look at their change controls over 12 months
and identify what proportion of those lead to risk reduction and continuous
improvements. Then they could quantify that e.g 90% lead to CI and risk reduction
etc. It would be great for a company to express change effectiveness in a way like
that.

3.1

Learnings from the SME Interviews

The SME’s were all in agreement that established conditions are a good idea. Having a
structured approach and an alligned definition, in advance, is helpful for planning how to
support changes. Also, it is helpful to know the requirements with respect to regulatory
submission notification in advance. Likewise, they were in agreement that the PACMP tool
would enhance transparancy with regulators by having the agreements upfront and this
would help with the implementation of change. Companies could have the oportunity to
down grade notifications and this would be a great benefit.
All three SME’s mentioned the complexity of the many regulatory authorities and a lack of
harmonisation among them.
In terms of the guidance from PIC/S, the SMEs observed that the paper goes a long way
towards giving companies solutions of how to demonstrate the effectiveness of their PQS
with regards to change management.
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Conclusion

One of the key enablers for ICH Q12 implementation is for a pharmaceutical company is to
have a robust change management process within their PQS that is capable of managing
changes. Therefore, PQS effectiveness must be demonstrated during regulatory inspections.
Industries One-Voice-of-Quality are speaking with a unified voice with a goal to harmonise
the approach for post approval change to overcome the problems of drug shortages and
their solutions paper describes specific details for the 4 PQS elements and 2 enablers on
how a company can leverage the PQS to effectively to manage post approval changes
through enhanced science and risk-based approaches.
The benefits of identifying and agreeing with regulatory agencies upon established
conditions enhances the speed at which continuous improvement could be made were
illustrated through the 2 case studies. This faster implementation of improvements can also
be acheived by the PACMP tool provides predictability regarding the information to support
a CMC change.
There is a lack of a harmonised approach on technical and regulatory considerations for
lifecycle management, which is a barrier to continuous improvement. Global regulatory
agreement on the requirements necessary for post approval changes to commerical drug
products is the first step towards achieving faster implementation of change. Regulatory
expectations worldwide allignment would be the ideal state in the pharmaceutical industry.
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